{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:46:32Z","timestamp":1760298392644},"reference-count":34,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2011]]},"DOI":"10.1536\/ihj.52.233","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T06:22:37Z","timestamp":1312957357000},"page":"233-239","source":"Crossref","is-referenced-by-count":13,"title":["Acute Effect of Sildenafil Is Maintained in Pulmonary Arterial Hypertension Patients Chronically Treated With Bosentan"],"prefix":"10.1536","volume":"52","author":[{"given":"Masaru","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.017"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gali&egrave; N, Brundage BH, Ghofrani HA, <i>et al<\/i>. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-903.","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005276847"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.013615"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64: 43-50.","DOI":"10.1007\/s00228-007-0408-z"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00003"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02383.x"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00051104"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2006.01692.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gruenig E, Michelakis E, Vachi&eacute;ry JL, <i>et al<\/i>. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009; 49: 1343-52.","DOI":"10.1177\/0091270009341182"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(01)00602-X"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.00318.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.","DOI":"10.1183\/09031936.00124007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Weitzberg E, Ahlborg G, Lundberg JM. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol 1993; 13: 653-62.","DOI":"10.1111\/j.1475-097X.1993.tb00480.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996; 94: 2077-82.","DOI":"10.1161\/01.CIR.94.9.2077"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pernow J, Hems&eacute;n A, Lundberg JM, Nowak J, Kaijser L. Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiol Scand 1991; 141: 319-24.","DOI":"10.1111\/j.1748-1716.1991.tb09087.x"},{"issue":"2","key":"18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.33.2.753","volume":"33","author":"CARDILLO C","year":"1999","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Verhaar MC, Strachan FE, Newby DE, <i>et al<\/i>. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752-6.","DOI":"10.1161\/01.CIR.97.8.752"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004; 43: 36-40.","DOI":"10.1161\/01.HYP.0000103868.45064.81"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nohria A, Garrett L, Johnson W, Kinlay S, Ganz P, Creager MA. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension 2003; 42: 43-8.","DOI":"10.1161\/01.HYP.0000074426.71392.D8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36: 1483-8.","DOI":"10.1016\/S0735-1097(00)00910-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680-3.","DOI":"10.1161\/01.CIR.100.16.1680"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. B&ouml;hm F, Johansson BL, Hedin U, Alving K, Pernow J. Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. Atherosclerosis 2002; 160: 215-22.","DOI":"10.1016\/S0021-9150(01)00564-0"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1161\/hc3501.095707"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000032260.01569.64"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cella G, Vianello F, Cozzi F, <i>et al<\/i>. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol 2009; 36: 760-7.","DOI":"10.3899\/jrheum.080542"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1002\/art.22634"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11024-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Voswinckel R, Reichenberger F, Enke B, <i>et al<\/i>. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008; 21: 824-32.","DOI":"10.1016\/j.pupt.2008.07.003"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ziolo MT, Lewandowski SJ, Smith JM, Romano FD, Wahler GM. Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 2003; 138: 986-94.","DOI":"10.1038\/sj.bjp.0705112"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Wang H, Kohr MJ, Traynham CJ, Ziolo MT. Phosphodiesterase 5 restricts NOS3\/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. J Mol Cell Cardiol 2009; 47: 304-14.","DOI":"10.1016\/j.yjmcc.2009.03.021"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.655266"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Qvigstad E, Moltzau LR, Aronsen JM, <i>et al<\/i>. Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 2010; 85: 763-72.","DOI":"10.1093\/cvr\/cvp364"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/ihj\/52\/4\/52_4_233\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T06:58:49Z","timestamp":1618815529000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/ihj\/52\/4\/52_4_233\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.52.233","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}